Purine metabolism as a target for leukemia chemotherapy

Michael Riscoe, M. C. Brouns, J. H. Fitchen

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

This article focuses on the chemotherapeutic agents which alter purine metabolism as a means to chieve selective killing of leukemic cells. We present an overview of purine metabolism in order to highlight enzymatic steps which are targeted by antileukemic drugs. Purine antimetabolites used in the treatment of leukemia can be grouped into three classes: (1) structural analogs of normal purines (6-mercaptopurine and 6-thioguanine); (2) inhibitors of de novo purine biosynthesis (methotrexate and hydroxyurea); and (3) inhibitors of purine salvage (2′-deoxycoformcin). In addition, a number of investigational drugs (trimetrexate, fludarabine and 2′-chlorodeoxyadenosine) have been recently introduced and show promise in early clinical trials. Purine antimetabolites are active in a variety of lymphoid and myeloid leukemias and represent an important component of the theraoy of these disorders. Several of the drugs have been developed with the specific intent of perturbing enzymes involved in purine metabolism. Refinements in our understanding of purine biochemistry in normal and leukemic cells may aid future efforts to design more effective drugs.

Original languageEnglish (US)
Pages (from-to)162-173
Number of pages12
JournalBlood Reviews
Volume3
Issue number3
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Leukemia
Drug Therapy
Antimetabolites
Trimetrexate
Pharmaceutical Preparations
Cladribine
Investigational Drugs
Lymphoid Leukemia
Thioguanine
6-Mercaptopurine
Purines
Myeloid Leukemia
Hydroxyurea
purine
Methotrexate
Biochemistry
Clinical Trials
Enzymes

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Purine metabolism as a target for leukemia chemotherapy. / Riscoe, Michael; Brouns, M. C.; Fitchen, J. H.

In: Blood Reviews, Vol. 3, No. 3, 1989, p. 162-173.

Research output: Contribution to journalArticle

Riscoe, Michael ; Brouns, M. C. ; Fitchen, J. H. / Purine metabolism as a target for leukemia chemotherapy. In: Blood Reviews. 1989 ; Vol. 3, No. 3. pp. 162-173.
@article{b41019be29fb45a2a7017f66461b29bb,
title = "Purine metabolism as a target for leukemia chemotherapy",
abstract = "This article focuses on the chemotherapeutic agents which alter purine metabolism as a means to chieve selective killing of leukemic cells. We present an overview of purine metabolism in order to highlight enzymatic steps which are targeted by antileukemic drugs. Purine antimetabolites used in the treatment of leukemia can be grouped into three classes: (1) structural analogs of normal purines (6-mercaptopurine and 6-thioguanine); (2) inhibitors of de novo purine biosynthesis (methotrexate and hydroxyurea); and (3) inhibitors of purine salvage (2′-deoxycoformcin). In addition, a number of investigational drugs (trimetrexate, fludarabine and 2′-chlorodeoxyadenosine) have been recently introduced and show promise in early clinical trials. Purine antimetabolites are active in a variety of lymphoid and myeloid leukemias and represent an important component of the theraoy of these disorders. Several of the drugs have been developed with the specific intent of perturbing enzymes involved in purine metabolism. Refinements in our understanding of purine biochemistry in normal and leukemic cells may aid future efforts to design more effective drugs.",
author = "Michael Riscoe and Brouns, {M. C.} and Fitchen, {J. H.}",
year = "1989",
doi = "10.1016/0268-960X(89)90013-1",
language = "English (US)",
volume = "3",
pages = "162--173",
journal = "Blood Reviews",
issn = "0268-960X",
publisher = "Churchill Livingstone",
number = "3",

}

TY - JOUR

T1 - Purine metabolism as a target for leukemia chemotherapy

AU - Riscoe, Michael

AU - Brouns, M. C.

AU - Fitchen, J. H.

PY - 1989

Y1 - 1989

N2 - This article focuses on the chemotherapeutic agents which alter purine metabolism as a means to chieve selective killing of leukemic cells. We present an overview of purine metabolism in order to highlight enzymatic steps which are targeted by antileukemic drugs. Purine antimetabolites used in the treatment of leukemia can be grouped into three classes: (1) structural analogs of normal purines (6-mercaptopurine and 6-thioguanine); (2) inhibitors of de novo purine biosynthesis (methotrexate and hydroxyurea); and (3) inhibitors of purine salvage (2′-deoxycoformcin). In addition, a number of investigational drugs (trimetrexate, fludarabine and 2′-chlorodeoxyadenosine) have been recently introduced and show promise in early clinical trials. Purine antimetabolites are active in a variety of lymphoid and myeloid leukemias and represent an important component of the theraoy of these disorders. Several of the drugs have been developed with the specific intent of perturbing enzymes involved in purine metabolism. Refinements in our understanding of purine biochemistry in normal and leukemic cells may aid future efforts to design more effective drugs.

AB - This article focuses on the chemotherapeutic agents which alter purine metabolism as a means to chieve selective killing of leukemic cells. We present an overview of purine metabolism in order to highlight enzymatic steps which are targeted by antileukemic drugs. Purine antimetabolites used in the treatment of leukemia can be grouped into three classes: (1) structural analogs of normal purines (6-mercaptopurine and 6-thioguanine); (2) inhibitors of de novo purine biosynthesis (methotrexate and hydroxyurea); and (3) inhibitors of purine salvage (2′-deoxycoformcin). In addition, a number of investigational drugs (trimetrexate, fludarabine and 2′-chlorodeoxyadenosine) have been recently introduced and show promise in early clinical trials. Purine antimetabolites are active in a variety of lymphoid and myeloid leukemias and represent an important component of the theraoy of these disorders. Several of the drugs have been developed with the specific intent of perturbing enzymes involved in purine metabolism. Refinements in our understanding of purine biochemistry in normal and leukemic cells may aid future efforts to design more effective drugs.

UR - http://www.scopus.com/inward/record.url?scp=0024424591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024424591&partnerID=8YFLogxK

U2 - 10.1016/0268-960X(89)90013-1

DO - 10.1016/0268-960X(89)90013-1

M3 - Article

VL - 3

SP - 162

EP - 173

JO - Blood Reviews

JF - Blood Reviews

SN - 0268-960X

IS - 3

ER -